Mersana Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview
26/02/2024 15:26
* Mersana Therapeutics Inc MRSN.OQ MRSN.O is expected
to show
a rise in quarterly revenue when it reports results on February
28 for the period ending December 31 2023
* The Cambridge Massachusetts-based company is expected to
report
a 0.6% increase in revenue to $14.772 million from $14.69
million a year ago, according to the mean estimate from 9
analysts, based on LSEG data.
* LSEG's mean analyst estimate for Mersana Therapeutics Inc
is
for a loss of 16 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 5
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Mersana
Therapeutics Inc is $3.00, below its last closing price
of $3.79.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.35 -0.36 -0.27 Beat 25.4
Jun. 30 2023 -0.37 -0.44 -0.47 Missed -6.5
Mar. 31 2023 -0.40 -0.44 -0.52 Missed -19.3
Dec. 31 2022 -0.47 -0.50 -0.44 Beat 12.8
Sep. 0.04 -0.09 -0.61 Missed -577.8
30 2022
Jun. 30 2022 -0.53 -0.52 -0.55 Missed -5.8
Mar. 31 2022 -0.32 -0.32 -0.59 Missed -85.2
Dec. 31 2021 -0.66 -0.67 -0.68 Missed -1.7
This summary was machine generated February 26 at 15:26 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)